Ketamine and buprenorphine show lasting effect against suicidal thoughts

A single ketamine infusion followed by low-dose buprenorphine appeared to do what suicide prevention medicine has struggled to deliver: hold down suicidal thoughts long enough to matter. In adults with major depressive disorder and clinically significant suicidal ideation, the drug sequence produced sustained reductions in suicidality over four weeks.

The study was published online May 19, 2026 in the American Journal of Psychiatry. Researchers enrolled 50 adults, gave each participant one open-label intravenous ketamine infusion, then randomized them 48 hours later to either low-dose buprenorphine or placebo for four weeks. The trial was described as the first randomized, double-blind, placebo-controlled study to show that a medication may help maintain and build on ketamine’s anti-suicidal effect.

That matters because ketamine already occupies a narrow but important place in suicide care. It can reduce suicidal thoughts within hours, a speed standard antidepressants usually cannot match, but the benefit typically fades quickly. Recent meta-analyses have continued to find rapid reductions in suicidal and depressive symptoms after intravenous ketamine, underscoring both its promise and its ceiling. Low-dose buprenorphine has also been investigated as a potential anti-suicidal treatment in major depression, giving the combination a plausible biological and clinical rationale.

The new results suggest a possible bridge over the treatment gap that leaves many high-risk patients waiting days or weeks for relief. A ClinicalTrials.gov-listed study, NCT04116528, had already hypothesized that buprenorphine after ketamine would produce stronger anti-suicidal effects and delay recurrence through four weeks of treatment. Stanford Medicine summarized the trial as involving 45 patients and said those who received buprenorphine had greater and longer-lasting reductions in suicidality than those given placebo.

Even so, the approach remains early-stage. Researchers and clinicians involved in the broader field of rapid-acting suicide prevention have stressed that it is not a substitute for emergency evaluation, close monitoring or comprehensive suicide prevention care. The central question now is whether a ketamine-plus-buprenorphine strategy can be proved durable, safe and practical enough to move from a promising experiment into routine clinical use.